双阳PLC编程培训学校,双阳PLC编程培训班分享PLC Medical Systems Names Lead Investigators for Pivotal Tri

双阳PLC编程培训学校招生详情：为您提供专业的双阳学PLC编程的学校，双阳PLC编程培训哪里好，双阳PLC编程培训学校，双阳PLC编程短期培训班，双阳PLC编程培训学校地址，双阳学PLC编程培训，双阳PLC编程培训哪里好，双阳PLC编程培训班，双阳PLC编程技术培训信息以及双阳PLC编程培训学校和双阳PLC编程培训班 新资讯，湖南阳光PLC编程培训学校，常年面向双阳地区开设PLC编程培训班，是专业的双阳PLC编程学校，常年面向双阳地区招生，热忱欢迎双阳地区的PLC编程技术求学者来我校学习 专业的PLC编程技术。双阳PLC编程培训学校，双阳PLC编程培训班，双阳PLC编程学校，双阳PLC编程培训学校，双阳PLC编程培训班哪家好，PLC Medical Systems Names Lead Investigators for Pivotal Tri。

双阳PLC编程培训班文章内容：

　　FRANKLIN, Mass., Dec. 19 /PRNewswire-FirstCall/ -- PLC Systems Inc. (Amex: PLC - News), a company focused on innovative cardiac and vascular medical device-based technologies, announced today that it has named two lead investigators for the upcoming pivotal trial of its RenalGuard Therapy(TM). The lead investigators are Charles Davidson, MD, Professor of Medicine, Northwestern University Medical School and Richard J. Solomon, MD, Professor of Medicine, University of Vermont College of Medicine. The trial is designed as a multi-center, prospective, randomized controlled trial to evaluate the effect of RenalGuard(TM) in the prevention of Contrast-Induced Nephropathy (CIN) during cardiovascular and peripheral imaging procedures performed in a catheterization lab. PLC intends to begin enrollment in the RenalGuard Pivotal Trial in early 2008, following receipt of the necessary approval from the U.S. Food & Drug Administration.

"Contrast-Induced Nephropathy is the third most common cause of in- hospital acute renal failure," stated Dr. Solomon. "The data on current prevention methods is largely inconclusive. It is our hope that this study will help determine the preventative benefits of RenalGuard Therapy in clinical use."

Dr. Davidson added, "CIN is a major issue for at-risk patients undergoing imaging procedures and can result in longer hospital stays and higher mortality rates. A cost-effective, easy-to-use preventive measure could reduce costs and save lives."

RenalGuard is an investigational system and therapy that targets patients with compromised renal function who may be at risk for CIN. RenalGuard Therapy is based on existing pre-clinical study data that suggests that initiating and maintaining high urine output during imaging procedures allows the body to rapidly eliminate toxins in contrast media, reducing their harmful effects. The RenalGuard System(TM) is a fully-automated, real-time matched fluid replacement device intended for interventional cardiology and radiology patients undergoing imaging procedures using contrast media.

PLC conducted a pilot study to confirm the safety of RenalGuard. Based upon the positive safety data collected in the pilot study and discussions with FDA, PLC stopped enrolling new patients in the pilot study and is preparing to submit a formal request to transition into a new pivotal trial protocol.

Contrast-Induced Nephropathy

Approximately seven million patients worldwide undergo interventional cardiovascular therapeutic and diagnostic imaging procedures each year. CIN is a major and growing problem due to the increasing number of older patients, diabetics and patients with pre-existing renal failure - all of whose conditions make them at risk for CIN when they require interventional procedures that use radiographic contrast media. CIN is the third most common cause of in-hospital acute renal failure. It is associated with significant in-hospital mortality rates, and increases in long-term mortality rates, major in-hospital adverse cardiac events, and the risk of having to undergo renal dialysis therapy. Any of these can result in prolonged hospital stays and increased medical costs. Studies indicate that approximately 15-20% of all patients undergoing image-guided cardiology and radiology procedures are at risk of developing CIN. The estimated mortality rate for patients that acquire CIN may be as high as 35%.

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world''s first TMR angina relief device cleared for commercial distribution by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare, and to obtain a CE Mark for European distribution.

The company conducted a pilot clinical safety study of its RenalGuard Therapy and RenalGuard System. RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys. This therapy is based on the theory that creating and maintaining a high urine output is beneficial to patients undergoing imaging procedures where contrast agents are used. The real-time measurement and matched fluid replacement design of the RenalGuard System is intended to ensure that a high urine flow is maintained before, during and after these procedures. This should allow the body to rapidly eliminate contrast, reducing its toxic effects. The RenalGuard System, with its matched fluid replacement capability, is intended to minimize the risk of over- or under-hydration.

Additional company information can be found at

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product, the clinical trials for that product may not be successful, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in our Report on Form 10-Q for the quarter ended September 30, 2007, and our other SEC reports.

PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser, RenalGuard, RenalGuard Therapy and RenalGuard System are trademarks of PLC Systems Inc.

Contact: Mary T. Conway Conway Communications 617-244-9682 mtconway@att.net

Source: PLC Systems Inc.
　　

，在这里告诉你一个好消息--湖南阳光技术学校全国招生。
一个老师决定学生变化的速度。好老师是学生成功的一半，在这里告诉你一个好消息--湖南阳光技术学校全国招生。
安置就业。颁发全国通用权威证书，在这里告诉你一个好消息--湖南阳光技术学校全国招生。
一个老师决定学生变化的速度。好老师是学生成功的一半，在这里告诉你一个好消息--湖南阳光技术学校全国招生。
学生在轻松的气氛中津津有味不知不觉地吸纳大量的知识，并且印象深刻，所学知识经久不忘；师生之间交流默契，学生乐学，我校老师乐教，在这里告诉你一个好消息--湖南阳光技术学校全国招生。
学校具有优良的办学条件，购建了充分满足专业课教学需要的各种实操室，在这里告诉你一个好消息--湖南阳光技术学校全国招生。
学校师资力量雄厚，注重教师队伍建设，有一只以杨澎、胡永林、李明、严若华、袁毅胥、杨海平、李宏贵、陈瑞强、唐贤佑、谭政、李明、康早新等理论水平高、专业技术精湛的专业教师队伍双阳PLC编程培训学校，双阳PLC编程培训班，双阳PLC编程学校，双阳学PLC编程的学校，双阳PLC编程培训哪里好，双阳PLC编程培训学校，双阳PLC编程短期培训班，双阳PLC编程培训学校地址，双阳学PLC编程培训，双阳PLC编程培训哪里好，双阳PLC编程培训班，双阳PLC编程技术培训.(编辑:hnygdzxx888)

双阳PLC编程学校延伸阅读： 。

(整理：双阳PLC编程培训学校)